Compare Gemini Space Station Inc (GEMI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Gemini Space Station Inc trades at $4.4 (market cap $579.55M), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 220.1× Gemini Space Station Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gemini Space Station Inc for 14 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| GEMI | VRTX | |
|---|---|---|
Market Cap | $579.55M | $127.55B |
Volume | 1,882,406 | 1,487,944 |
Sector | Financials | Health |
52-Week High | $23.45 | $557.96 |
52-Week Low | $3.54 | $407.37 |
Typical Hold Time | 14 Days | 120 Days |
Enterprise Value | $558.57M | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.47, down 0.45% with a bearish technical outlook. The company reported Q2 2026 revenue growth of 37% year-over-year to $207 million but continues to post significant losses with a net income margin of -250.13%. Recent news highlights expansion into commission-free stock trading and prediction markets, though the stock faces class action lawsuits and mixed analyst sentiment.
Investment outlook remains cautious due to persistent unprofitability and legal challenges. The consensus price target of $5.25 offers 17% upside potential, but high cash burn and negative margins pose substantial risks. Wall Street is divided with 33% buy ratings amid ongoing operational challenges and competitive pressures in financial services.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, amid a bearish technical signal but strong fundamentals. The company reported $12.0B revenue and $4.0B net income for 2025, with robust profitability margins. Recent positive Phase 2b trial results for its kidney disease drug inaxaplin highlight pipeline progress. Support and resistance levels are tightly clustered around the current price, indicating potential for near-term volatility.
Outlook remains positive given dominant cystic fibrosis franchise, high margins, and promising pipeline, though earnings misses and competitive pressures pose risks. Analyst consensus is strongly bullish with a $573.50 price target, suggesting ~14% upside. Key risks include clinical trial outcomes and reliance on core franchise growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
